Delcath Systems (NASDAQ: DCTH) is a specialty oncology medical device company that develops and commercializes a hepatic delivery system for treating cancers of the liver. Revenue is generated through the sale of its HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), a combination drug-device product approved by the U.S. Food and Drug Administration. The filing, a 10-K for the fiscal year ended and filed 2026-02-26 (accession 000162828026012019), lists the company on The Nasdaq Capital Market under the ticker DCTH. Delcath operates in the interventional oncology segment, focused on isolated hepatic perfusion as a treatment modality. The filing excerpts do not provide sufficient detail to characterize revenue figures, customer concentration, geographic mix, competitive set, founding year, or current leadership with confidence, so those details are omitted here.

Revenue model

Product sales of the HEPZATO KIT, a combined drug-device system used in hepatic delivery procedures, as disclosed in the 10-K filed 2026-02-26.

Products and services

HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), an FDA-approved combination drug-device product for liver cancer treatment.

Customers and end markets

Oncology and interventional radiology settings treating patients with cancers of the liver, based on the product indication disclosed in the 10-K filed 2026-02-26.

Value-chain role

Medical device and drug-device combination product manufacturer and commercializer in the interventional oncology space.

Geographic exposure

Listed on The Nasdaq Capital Market; specific geographic revenue breakdown not supported by the filing excerpts provided.

Source: SEC 10-K, filed 2026-02-26

Industry: Surgical & Medical Instruments & Apparatus Peers: Abbott Laboratories Acutus Medical, Inc. ALR TECHNOLOGIES INC. REMSleep Holdings Inc Streamex Corp Sonendo, Inc. Strata Skin Sciences Inc OMNIA WELLNESS INC. MINERVA SURGICAL INC NeuroOne Medical Technologies Corp